 RespireRx Pharmaceuticals OTC:RSPI Inc said that as of January 11, 2023, it has established a new, currently wholly-owned, unlisted public company in Australia called ResolutionRX. The company said that this is the first in a series of steps all for the purpose of developing compounds that target the bodys endocannabinoid system, in particular the repurposing of dronabinol which as an endocannabinoid CB1 and CB2 receptor agonist, for the treatment of obstructive sleep apnea. 